» Articles » PMID: 9807980

Comparison of the Single-dose Pharmacokinetics and Tolerability of Modafinil and Dextroamphetamine Administered Alone or in Combination in Healthy Male Volunteers

Overview
Publisher Wiley
Specialty Pharmacology
Date 1998 Nov 10
PMID 9807980
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

An open-label, randomized, crossover study was performed in healthy male volunteers to evaluate the potential pharmacokinetic and pharmacodynamic interactions and tolerability of single oral doses of modafinil (200 mg) and dextroamphetamine (10 mg). Blood samples were collected for determination of plasma levels of modafinil, the acid and sulfone metabolites of modafinil, and dextroamphetamine at intervals through 48 hours after administration for each treatment. Vital signs (blood pressure and pulse rate) were measured through 48 hours, and electrocardiograms were measured through 24 hours after administration. Pharmacokinetic parameters were determined using noncompartmental methods. The data collected in this study of 24 healthy volunteers suggest that concomitant administration of single oral doses of modafinil and dextroamphetamine has no clinically significant effects on the pharmacokinetic profile of either agent. Although there was a slightly greater incidence of adverse events when modafinil and dextroamphetamine were administered together, the concomitant administration of the two drugs was well tolerated.

Citing Articles

The relationship between novelty-seeking traits and behavior: Establishing construct validity for the human Behavioral Pattern Monitor.

Minassian A, Kelsoe J, Miranda A, Young J, Perry W Psychiatry Res. 2022; 316:114776.

PMID: 35964417 PMC: 9885942. DOI: 10.1016/j.psychres.2022.114776.


Pharmacotherapeutic strategies for treating cocaine use disorder-what do we have to offer?.

Brandt L, Chao T, Comer S, Levin F Addiction. 2020; 116(4):694-710.

PMID: 32888245 PMC: 7930140. DOI: 10.1111/add.15242.


Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.

Schoretsanitis G, De Leon J, Eap C, Kane J, Paulzen M CNS Drugs. 2019; 33(12):1201-1222.

PMID: 31776871 DOI: 10.1007/s40263-019-00683-7.


Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol.

Rowland A, van Dyk M, Warncken D, Mangoni A, Sorich M, Rowland A Br J Clin Pharmacol. 2017; 84(3):501-509.

PMID: 29178272 PMC: 5809348. DOI: 10.1111/bcp.13478.


Amphetamine Modestly Improves Conners' Continuous Performance Test Performance in Healthy Adults.

MacQueen D, Minassian A, Henry B, Geyer M, Young J, Perry W J Int Neuropsychol Soc. 2017; 24(3):283-293.

PMID: 29032769 PMC: 5820221. DOI: 10.1017/S135561771700090X.